Review Article| Volume 22, ISSUE 1, P56-64, January 2021

Anticholinergic Burden Measures Predict Older People's Physical Function and Quality of Life: A Systematic Review



      This systematic review (PROSPERO CRD42019115918) compared the evidence behind anticholinergic burden (ACB) measures and their ability to predict changes in older people's physical function and quality of life.


      Eligible cohort or case-control studies were identified systematically using comprehensive search terms and a validated search filter for prognostic studies. Medline (OVID), EMBASE (OVID), CINAHL (EMBSCO), and PsycINFO (OVID) databases were searched. Risk of bias, using Quality in Prognosis Studies tool, and quality of evidence, using the Grading of Recommendations, Assessment, Development and Evaluation, were assessed.

      Setting and Participants

      People aged 65 years and older from any clinical setting.


      Any ACB measures were accepted (including the anticholinergic domain of the Drug Burden Index). Any global/multidimensional measure for physical function and/or quality of life was accepted for outcome.


      Thirteen studies reporting associations between ACB and physical function (n = 10) or quality of life (n = 4) were included. Exposure measures included Anticholinergic Cognitive Burden Scale, Anticholinergic Drug Scale, Anticholinergic Risk Scale, Clinician Rated Anticholinergic Score, and the anticholinergic domain of the Drug Burden Index. All studies were rated moderate risk of bias in ≥2 Quality in Prognosis Studies categories with 5 rated high risk in ≥1 categories. Seven of 10 studies (5251 of 7569 participants) reported significant decline in physical function with increased burden. All 4 studies (2635 participants) reporting quality of life demonstrated similar association with increased burden. High risk of biases and inadequate data reporting restricted analysis. There was no evidence to support one measure being superior to another.

      Conclusions and Implications

      The evidence supports association between increased ACB and future impairments in physical function and quality of life. No conclusion can be made regarding which ACB measure has the best prognostic value. Well-designed longitudinal studies are required to address this. Clinicians should be aware of patient's anticholinergic burden and consider alternative medications where appropriate.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of the American Medical Directors Association
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Akishita M.
        • Ishii S.
        • Kojima T.
        • et al.
        Priorities of health care outcomes for the elderly.
        JAMDA. 2013; 14: 479-484
        • World Health Organization
        Towards a Common Language for Functioning, Disability and Health. The International Classification of Functioning, Disability and Health.
        World Health Organization, Geneva2002 (Available at:)
        • World Health Organization
        WHOQOL: Measuring Quality of Life.
        (Available at:)
        • Cieza A.
        • Stucki G.
        Content comparison of health-related quality of life (HRQOL) instruments based on the international classification of functioning, disability and health (ICF).
        Qual Life Res. 2005; 14: 1225-1237
        • Fox C.
        • Smith T.
        • Maidment I.
        • et al.
        Effect of medications with anti-cholinergic properties on cognitive function, delirium, physical function and mortality: A systematic review.
        Age Ageing. 2014; 43: 604-615
        • Wouters H.
        • van der Meer H.
        • Taxis K.
        Quantification of anticholinergic and sedative drug load with the Drug Burden Index: A review of outcomes and methodological quality of studies.
        Eur J Clin Pharmacol. 2017; 73: 257-266
        • Kersten H.
        • Wyller T.B.
        Anticholinergic drug burden in older people's brain–How well is it measured?.
        Basic Clin Pharmacol. 2014; 114: 151-159
        • Kouladjian O'Donnell L.
        • Gnjidic D.
        • Nahas R.
        • et al.
        Anticholinergic burden: Considerations for older adults.
        J Pharm Prac Res. 2017; 47: 67-77
        • Gerretsen P.
        • Pollock B.G.
        Cognitive risks of anticholinergics in the elderly.
        Ageing Health. 2013; 9: 159-166
        • Lampela P.
        • Lavikainen P.
        • Garcia-Horsman J.A.
        • et al.
        Anticholinergic drug use, serum anticholinergic activity, and adverse drug events among older people: A population-based study.
        Drugs Aging. 2013; 30: 321-330
        • Merchant R.A.
        • Li B.
        • Yap K.B.
        • Ng T.P.
        Use of drugs with anticholinegic effects and cognitive impairment in community-living older persons.
        Age Ageing. 2008; 38: 105-108
        • Cardwell K.
        • Hughes C.M.
        • Ryan C.
        The association between anticholinergic medication burden and health related outcomes in the ‘oldest old’: A systematic review of the literature.
        Drug Aging. 2015; 32: 835-848
        • Salahudeen M.S.
        • Duffull S.B.
        • Nishtala P.S.
        Anticholinergic burden quantified by anticholinergic risk scales and adverse outcomes in older people: A systematic review.
        BMC Geriatr. 2015; 15: 31
        • Boustani M.
        • Campbell N.
        • Munger S.
        • et al.
        Impact of anticholinergics on the aging brain: A review and practical application.
        Ageing Health. 2008; 4: 311-320
        • Rudolph J.L.
        • Salow M.J.
        • Angelini M.C.
        • McGlinchey R.E.
        The anticholinergic risk scale and anticholinergic adverse effects in older persons.
        Arch Int Med. 2008; 168: 508-513
      1. Cochrane Prognostic Review Group Framework for Prognostic Reviews. Review Tools.
        (Available at:)
        • Geersing G.J.
        • Bouwmeester W.
        • Zuithoff P.
        • et al.
        Search filters for finding prognostic and diagnostic prediction studies in Medline to enhance systematic reviews.
        PLoS One. 2012; 7: e32844
        • Welsh T.J.
        • van der Wardt V.
        • Ojo G.
        • et al.
        Anticholinergic drug burden tools/scales and adverse outcomes in different clinical settings: A systematic review of reviews.
        Drugs Aging. 2018; 35: 523-538
        • Quality in Prognosis Studies (QUIPS)
        QUIPS Assessment Tool.
        (Available at:)
        • Popay J.
        • Roberts H.
        • Sowden A.
        • et al.
        Guidance on the conduct of narrative synthesis in systematic reviews. A product from the ESRC methods programme Version, 1, b92.
        2006 (Available at:)
        • Guyatt G.H.
        • Oxman A.D.
        • Vist G.E.
        • et al.
        GRADE: An emerging consensus on rating quality of evidence and strength of recommendations.
        BMJ. 2008; 336: 924-926
        • Huguet A.
        • Hayden J.A.
        • Stinson J.
        • et al.
        Judging the quality of evidence in reviews of prognostic factor research: Adapting the GADE framework.
        Sys Rev. 2013; 2: 71
        • Agar M.
        • Currow D.
        • Plummer J.
        • et al.
        Changes in anticholinergic load from regular prescribed medications in palliative care as death approaches.
        Palliative Med. 2009; 23: 257-265
        • Brombo G.
        • Bianchi L.
        • Maietti E.
        • et al.
        Association of anticholinergic drug burden with cognitive and functional decline over time in older inpatients: Results from the CRIME Project.
        Drug Aging. 2018; 35: 917-924
        • Cossette B.
        • Bagna M.
        • Sene M.
        • et al.
        Association between anticholinergic drug use and health-related quality of life in community-dwelling older adults.
        Drug Aging. 2017; 34: 785-792
        • Han L.
        • Agostini J.V.
        • Allore H.G.
        Cumulative anticholinergic exposure is associated with poor memory and executive function in older men.
        JAGS. 2008; 56: 2203-2210
        • Hershkovitz A.
        • Angel C.
        • Brill S.
        • Nissan R.
        The Association between Anticholinergic Drug Use and Rehabilitation Outcome in Post-Acute Hip Fractured Patients: A Retrospective Cohort Study.
        Drugs Aging. 2018; 35: 333-341
        • Ie K.
        • Chou E.
        • Boyce R.D.
        • Albert S.M.
        Potentially harmful medication use and decline in health related quality of life among community-dwelling older adults.
        Drugs Real World Outcomes. 2017; 4: 257-264
        • Kolanowski A.
        • Mogle J.
        • Fick D.M.
        • et al.
        Anticholinergic exposure during rehabilitation: Cognitive and physical function outcomes in patients with delirium superimposed on dementia.
        Am J Geriatr Psychiatry. 2015; 23: 1250-1258
        • Koshoedo S.
        • Soiza R.L.
        • Purkayastha R.
        • Mangoni A.A.
        Anticholinergic drugs and functional outcomes in older patients undergoing orthopaedic rehabilitation.
        AM J Geriatr Pharmacol. 2012; 10: 251-257
        • Koyama A.
        • Steinman M.
        • Ensrud K.
        • et al.
        Long-term cognitive and functional effects of potentially inappropriate medications in older women.
        J Gerontol A Biol Sci Med Sci. 2014; 69: 423-429
        • Landi F.
        • Dell'Aquila G.
        • Collamati A.
        • et al.
        Anticholinergic drug use and negative outcomes among the frail elderly population living in a nursing home.
        JAMDA. 2014; 15: 825-829
        • Lopez-Matons N.
        • Conill Badell D.
        • Obrero Cusido G.
        • et al.
        Anticholinergic drugs and cognitive impairment in the elderly.
        Medicina Clinica. 2018; 151: 141-144
        • Pasina L.
        • Djade C.D.
        • Lucca U.
        • et al.
        Association of anticholinergic burden with cognitive and functional status in a cohort of hospitalized elderly: Comparison of the anticholinergic cognitive burden scale and anticholinergic risk scale: Results from the REPOSI study.
        Drugs Aging. 2013; 30: 103-112
        • Sura S.D.
        • Carnahan R.M.
        • Chen H.
        • Aparasu R.R.
        Anticholinergic drugs and health-related quality of life in older adults with dementia.
        J Am Pharm Assoc. 2015; 55: 282-287
        • Zia A.
        • Kamaruzzaman S.
        • Myint P.K.
        • Tan M.P.
        Anticholinergic burden is associated with recurrent and injurious falls in older individuals.
        Maturitas. 2016; 84: 32-37
        • Makovski T.T.
        • Schmitz S.
        • Zeegers M.P.
        • et al.
        Multimorbidity and quality of life: Systematic literature review and meta-analysis.
        Age Res Rev. 2019; 53: 100903
        • Villalba-Moreno A.M.
        • Alfaro-Lara E.R.
        • Pérez-Guerrero M.C.
        • et al.
        Systematic review on the use of anticholinergic scales in poly pathological patients.
        Arch Gerontol Geriatr. 2016; 62: 1-8
        • Tolea M.I.
        • Morris J.C.
        • Galvin J.E.
        Longitudinal associations between physical and cognitive performance among community-dwelling older adults.
        Plos One. 2015; 10: e0122878
        • Stites S.D.
        • Harkins K.
        • Rubright J.D.
        • Karlawish J.
        Relationships between cognitive complaints and quality of life in older adults with mild cognitive impairment, mild Alzheimer disease dementia, and normal cognition.
        Alzheimer Dis Assoc Disord. 2018; 32: 276-283